JAZZ
Jazz Pharmaceuticals plc
$127.75
+$1.62(+1.28%)
68
Overall
80
Value
75
Tech
50
Quality
Market Cap
$7.58B
Volume
675.58K
52W Range
$95.49 - $148.06
Target Price
$186.44
Order:
Income Statement
| Metric | Trend | Chart | 2015 Dec | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $1.3B | $1.5B | $1.6B | $1.9B | $2.2B | $2.4B | $3.1B | $3.7B | $3.8B | $4.1B | ||
| Total Revenue | $1.3B | $1.5B | $1.6B | $1.9B | $2.2B | $2.4B | $3.1B | $3.7B | $3.8B | $4.1B | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | -- | -- | -- | $121.5M | $-127.9M | $-148.9M | $-440.8M | $540.5M | $435.6M | $445.7M | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $1.3B | $1.5B | $1.6B | $1.8B | $2.3B | $2.2B | $2.7B | $3.1B | $3.8B | $3.6B | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $-816.6M | $-896.3M | $-1.1B | $1.1B | $1.5B | $1.7B | $2.5B | $2.6B | $2.8B | $2.9B | ||
| Research & Development | $135.3M | $186.0M | $283.4M | $226.6M | $409.7M | $586.6M | $505.7M | $1.0B | $868.7M | $894.0M | ||
| Research Expense | $135.3M | $162.3M | $198.4M | $226.6M | $299.7M | $335.4M | $505.7M | $590.5M | $849.7M | $884.0M | ||
| Selling, General & Administrative | $449.1M | $502.9M | $544.2M | $683.5M | $736.9M | $854.2M | $1.5B | $1.4B | $1.3B | $1.4B | ||
| Selling & Marketing Expenses | $449.1M | $502.9M | $544.2M | $683.5M | $65.4M | $99.6M | $161.5M | $108.8M | $92.2M | $107.4M | ||
| General & Administrative Expenses | $-10.5M | $-11.6M | $-15.0M | $-11.5M | $736.9M | $854.2M | $1.5B | $1.4B | $1.3B | $1.4B | ||
| Promotion & Advertising | $-27.9M | $-29.5M | $-36.6M | $-37.4M | $65.4M | $99.6M | $161.5M | $108.8M | $92.2M | $107.4M | ||
| Salaries & Wages | $-91.5M | $-98.8M | $-106.9M | $-102.4M | $-15.7M | $-12.8M | $-34.0M | $-41.1M | $-40.0M | $-40.6M | ||
| Depreciation & Amortization | $98.2M | $102.0M | $152.1M | $201.5M | $354.8M | $259.6M | $525.8M | $599.2M | $608.3M | $627.3M | ||
| Depreciation & Amortization | $98.2M | $102.0M | $152.1M | $201.5M | $354.8M | $259.6M | $525.8M | $599.2M | $608.3M | $627.3M | ||
| Amortization | $98.2M | $102.0M | $152.1M | $201.5M | $354.8M | $259.6M | $525.8M | $599.2M | $608.3M | $627.3M | ||
| Other Operating Expenses | $102.5M | $105.4M | $110.2M | $-22.6M | $-27.6M | $-27.9M | $-26.7M | $-25.1M | $-15.0M | $-32.6M | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $539.7M | $591.7M | $528.8M | $657.7M | $532.4M | $378.1M | $170.3M | $-65.5M | $578.6M | $716.6M | ||
| EBITDA | $566.7M | $640.9M | $598.5M | $733.5M | $930.0M | $653.1M | $718.4M | $535.0M | $934.0M | $1.1B | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | -- | $-27.5M | $-37.8M | $-56.7M | $59.1M | $99.7M | $278.8M | $288.2M | $377.0K | $442.0K | ||
| Intinc | $-56.9M | $-61.9M | $-77.8M | $-77.1M | $-72.3M | $-99.7M | $-278.8M | $-288.2M | $-289.4M | $-238.1M | ||
| Net Non-Operating Interest Income/Expense | $-56.9M | $-61.9M | $-77.8M | $-77.1M | $-72.3M | $-99.7M | $-278.8M | $-288.2M | $-289.4M | $-238.1M | ||
| Gain on Sale of Securities | $-16.8M | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Other Income/Expense | $16.8M | $1.0M | $1.0M | $3.6M | $4.1M | $3.0M | $714.0K | $-596.8M | $3.0M | $1.7M | ||
| Other Special Charges | $1.4M | -- | -- | $7.5M | $5.4M | $4.7M | $2.8M | $2.1M | -- | -- | ||
| SPECIAL ITEMS | ||||||||||||
| Restructring And Mn A Income | $-1.6M | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Special Income Charges | $-31.5M | -- | -- | $-42.9M | -- | $-136.1M | -- | $-133.6M | -- | -- | ||
| Impairment of Capital Assets | $31.5M | -- | -- | $42.9M | -- | $136.1M | -- | $133.6M | -- | -- | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $435.9M | $504.9M | $403.3M | $472.8M | $513.4M | $374.8M | $165.9M | $-94.5M | $295.3M | $469.1M | ||
| Pre-Tax Income | $435.9M | $532.4M | $441.1M | $529.5M | $454.3M | $275.1M | $-112.8M | $-372.8M | $297.9M | $470.4M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | $106.4M | $135.2M | $-47.7M | $80.2M | $-73.2M | $33.5M | $216.1M | $-158.6M | $-119.9M | $-91.4M | ||
| NET INCOME | ||||||||||||
| Net Income | $329.5M | $396.8M | $487.8M | $447.1M | $523.4M | $238.6M | $-329.7M | $-224.1M | $414.8M | $560.1M | ||
| Net Income (Continuing Operations) | $329.5M | $396.8M | $487.8M | $447.1M | $523.4M | $238.6M | $-329.7M | $-224.1M | $414.8M | $560.1M | ||
| Net Income (Discontinued Operations) | $329.5M | $396.8M | $487.8M | $447.1M | $523.4M | $238.6M | $-329.7M | $-224.1M | $414.8M | $560.1M | ||
| Net Income (Common Stockholders) | $329.5M | $396.8M | $487.8M | $447.1M | $779.2M | $238.6M | $-329.7M | $-224.1M | $414.8M | $560.1M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | -- | -- | -- | $378.9M | ||
| TOTALS | ||||||||||||
| Total Expenses | $-816.6M | $-896.3M | $-1.1B | $1.2B | $1.4B | $1.6B | $2.0B | $3.1B | $2.8B | $2.9B | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $61.2M | $60.5M | $60.0M | $60.0M | $56.7M | $55.7M | $59.7M | $62.5M | $63.3M | $61.8M | ||
| Average Shares Outstanding (Diluted) | $63.0M | $61.9M | $61.3M | $61.2M | $57.5M | $56.5M | $59.7M | $62.5M | $72.1M | $66.0M | ||
| Shares Outstanding | $61.2M | $59.7M | $59.8M | $57.1M | $56.1M | $56.3M | $61.7M | $63.3M | $62.3M | $60.7M | ||
| Basic EPS | $5.38 | $6.56 | $8.13 | $7.45 | $9.22 | $4.28 | $-5.52 | $-3.58 | $6.55 | $9.06 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | -- | $9.22 | $4.28 | $-5.52 | $-3.58 | $6.55 | $9.06 | ||
| Diluted EPS | $5.23 | $6.41 | $7.96 | $7.3 | $9.09 | $4.22 | $-5.52 | $-3.58 | $6.1 | $8.65 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | -- | $9.09 | $4.22 | $-5.52 | $-3.58 | $6.1 | $8.65 | ||
| OTHER METRICS | ||||||||||||
| Acquired In Process Rn D Income | -- | $-638.0K | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Development Expense | -- | $23.8M | $85.0M | -- | $110.0M | $251.3M | -- | $444.1M | $19.0M | $10.0M | ||
| Earnings from equity interest | -- | $-379.0K | $-1.0M | $-3.6M | $-4.1M | $-3.0M | $-714.0K | $-9.9M | $-3.0M | $-1.7M | ||
| Earnings From Equity Interest Net Of Tax | -- | $-379.0K | $-1.0M | $-3.6M | $-4.1M | $-3.0M | $-714.0K | $-9.9M | $-3.0M | $-1.7M | ||
| Gain On Sale Of Business | -- | $-638.0K | $100.0K | $-1.4M | -- | -- | -- | -- | -- | -- | ||
| Gain On Sale Of P P E | -- | -- | $-473.0K | $-655.0K | $-21.0K | -- | -- | -- | -- | -- | ||
| Minority Interests | $1.0K | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Other Gand A | $-10.5M | $-11.6M | $-15.0M | $-11.5M | $736.9M | $854.2M | $1.5B | $1.4B | $1.3B | $1.4B | ||
| Rent And Landing Fees | $-10.5M | $-11.6M | $-15.0M | $-11.5M | -- | -- | -- | -- | -- | -- | ||
| Selling Expense | $449.1M | $502.9M | $544.2M | $683.5M | -- | -- | -- | -- | -- | -- | ||
| Write Down | -- | -- | -- | -- | -- | -- | -- | $-12.9M | -- | -- | ||
| Restruct | $-1.6M | -- | -- | -- | -- | -- | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | JAZZ | $127.75 | +1.3% | 675.58K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Jazz Pharmaceuticals plc Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW